# Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance

> **NCT01295333** · PHASE3 · COMPLETED · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 200 (actual)

## Conditions studied

- Graves Disease (Basedow's Disease)

## Interventions

- **DRUG:** the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation
- **DRUG:** The initiation of LT4 as soon as the first biological signs of hypothyroidism.

## Key facts

- **NCT ID:** NCT01295333
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2014-11
- **Final completion:** 2014-12
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2015-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01295333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01295333, "Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT01295333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*